SYRS Syros Pharmaceuticals, Inc. revenue, earnings and financials
For the quarter ended September 30, 2024, Syros Pharmaceuticals, Inc. reported revenue of n/a, net income of −$6.40M and diluted EPS of −$0.16; for the fiscal year ended December 2023 revenue was $9.94M, down 33.2% on the year before.
SYRS annual revenue and earnings
- Fiscal year ended Dec 2023: revenue $9.94M, gross profit n/a, operating income −$129M, net income −$165M (margin -1656.3%), EPS −$5.81
- Fiscal year ended Dec 2022: revenue $14.9M, gross profit n/a, operating income −$136M, net income −$94.7M (margin -636.1%), EPS −$7.49
- Fiscal year ended Dec 2021: revenue $23.5M, gross profit n/a, operating income −$99.4M, net income −$86.6M (margin -368.5%), EPS −$13.84
SYRS quarterly revenue and earnings
- Quarter ended Sep 30, 2024: revenue n/a, net income −$6.40M, EPS −$0.16
- Quarter ended Jun 30, 2024: revenue n/a, net income −$23.3M, EPS −$0.59
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.71M, EPS −$0.10
- Quarter ended Dec 31, 2023 (from the annual report): revenue $387K (up 151.3% year over year), net income −$64.4M, EPS −$2.23
- Quarter ended Sep 30, 2023: revenue $3.76M (down 3.3% year over year), net income −$40.1M, EPS −$1.43
- Quarter ended Jun 30, 2023: revenue $2.83M (down 54.9% year over year), net income −$36.3M, EPS −$1.30
- Quarter ended Mar 31, 2023: revenue $2.95M (down 46.0% year over year), net income −$23.8M, EPS −$0.85
- Quarter ended Dec 31, 2022 (from the annual report): revenue −$754K (down 109.7% year over year), net income −$4.77M, EPS $5.11
- Quarter ended Sep 30, 2022: revenue $3.89M (down 31.7% year over year), net income −$30.3M, EPS −$3.21
- Quarter ended Jun 30, 2022: revenue $6.28M (up 21.6% year over year), net income −$34.5M, EPS −$5.40
- Quarter ended Mar 31, 2022: revenue $5.47M (up 13.3% year over year), net income −$25.1M, EPS −$3.99
- Quarter ended Dec 31, 2021 (from the annual report): revenue $7.80M, net income −$23.8M, EPS −$9.11
- Quarter ended Sep 30, 2021: revenue $5.70M, net income −$26.0M, EPS −$4.14
- Quarter ended Jun 30, 2021: revenue $5.16M, net income −$22.5M, EPS −$0.36
- Quarter ended Mar 31, 2021: revenue $4.83M, net income −$14.2M, EPS −$0.23
SYRS cash flow, buybacks and dividends
- Fiscal year ended Dec 2023: operating cash flow −$110M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$123M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$99.5M, share buybacks n/a
SYRS balance sheet
- Sep 30, 2024: cash $58.3M, total assets $85.0M, total liabilities n/a, shareholders' equity −$11.1M, long-term debt $41.1M
- Jun 30, 2024: cash $79.0M, total assets $107M, total liabilities n/a, shareholders' equity −$6.35M, long-term debt $40.9M
- Mar 31, 2024: cash $83.5M, total assets $135M, total liabilities n/a, shareholders' equity $15.1M, long-term debt $29.7M
- Dec 31, 2023: cash $140M, total assets $168M, total liabilities n/a, shareholders' equity $16.7M, long-term debt $34.6M
- Sep 30, 2023: cash $112M, total assets $148M, total liabilities n/a, shareholders' equity $36.3M, long-term debt $39.4M
- Jun 30, 2023: cash $115M, total assets $181M, total liabilities n/a, shareholders' equity $73.2M, long-term debt $40.9M
- Mar 31, 2023: cash $105M, total assets $205M, total liabilities n/a, shareholders' equity $107M, long-term debt $39.1M
- Dec 31, 2022: cash $167M, total assets $244M, total liabilities n/a, shareholders' equity $128M, long-term debt $40.6M
What is SYRS's revenue?
Syros Pharmaceuticals, Inc. reported $9.94M of revenue for the fiscal year ended December 2023.
Is SYRS profitable?
No. Syros Pharmaceuticals, Inc. lost $97.8M over the last four quarters.
What is SYRS's EPS?
Diluted earnings per share over the last four quarters were −$3.08; −$0.16 in the latest quarter.